Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program - PubMed

Affiliations

• PMID: 18721775
• DOI: 10.1016/j.bbmt.2008.06.006

Free article

Review

Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program

Chatchada Karanes et al. Biol Blood Marrow Transplant. 2008 Sep.

Free article

Abstract

For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients. In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs). The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years. Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients. Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML. Treatment-related mortality (TRM) has declined significantly over the years, particularly in association with myeloablative transplant preparative regimens. Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years.

Similar articles

• Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program.

  MacMillan ML, Davies SM, Nelson GO, Chitphakdithai P, Confer DL, King RJ, Kernan NA. MacMillan ML, et al. Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):16-22. doi: 10.1016/j.bbmt.2008.05.019. Biol Blood Marrow Transplant. 2008. PMID: 18721776 Review.

• The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation.

  Ballen KK, King RJ, Chitphakdithai P, Bolan CD Jr, Agura E, Hartzman RJ, Kernan NA. Ballen KK, et al. Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):2-7. doi: 10.1016/j.bbmt.2008.05.017. Biol Blood Marrow Transplant. 2008. PMID: 18721774

• National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants.

  Bray RA, Hurley CK, Kamani NR, Woolfrey A, Müller C, Spellman S, Setterholm M, Confer DL. Bray RA, et al. Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):45-53. doi: 10.1016/j.bbmt.2008.06.014. Biol Blood Marrow Transplant. 2008. PMID: 18721780 Review. No abstract available.

• Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO).

  Dini G, Cancedda R, Giorgiani G, Porta F, Messina C, Uderzo C, Pession A, Fagioli F, La Nasa G, Arcese W, Pollichieni S, Zecca M, Lanino E, Mazzolari E, Cesaro S, Balduzzi A, Rondelli R, Vassallo E, Cappelli B, Locatelli F; Association Italiana Ematologia e Oncologia Pediatrica and Gruppo Italiano per il Trapianto Midollo Osseo. Dini G, et al. Haematologica. 2002 Aug;87(8 Suppl):51-7. Haematologica. 2002. PMID: 12412391

• Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

  Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Warlick ED, et al. Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012. Biol Blood Marrow Transplant. 2009. PMID: 19135940

Cited by

• BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.

  Li Q, Wu Y, Fang S, Wang L, Qi H, Zhang Y, Zhang J, Li W. Li Q, et al. Cancer Gene Ther. 2015 May;22(5):227-37. doi: 10.1038/cgt.2014.65. Epub 2015 Apr 3. Cancer Gene Ther. 2015. PMID: 25837664

• Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).

  Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Saber W, et al. Blood. 2013 Sep 12;122(11):1974-82. doi: 10.1182/blood-2013-04-496778. Epub 2013 Jul 11. Blood. 2013. PMID: 23847196 Free PMC article.

• Leukemia stem cells: the root of chronic myeloid leukemia.

  Zhou H, Xu R. Zhou H, et al. Protein Cell. 2015 Jun;6(6):403-12. doi: 10.1007/s13238-015-0143-7. Epub 2015 Mar 10. Protein Cell. 2015. PMID: 25749979 Free PMC article. Review.

• T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.

  Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, Hsu KC, Perales MA, Papanicolaou G, van den Brink MR, O'Reilly RJ, Young JW, Papadopoulos EB. Jakubowski AA, et al. Biol Blood Marrow Transplant. 2011 Sep;17(9):1335-42. doi: 10.1016/j.bbmt.2011.01.005. Epub 2011 Jan 11. Biol Blood Marrow Transplant. 2011. PMID: 21232623 Free PMC article. Clinical Trial.

• Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

  Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Schlaak M, et al. Cochrane Database Syst Rev. 2013 Aug 29;2013(8):CD008908. doi: 10.1002/14651858.CD008908.pub3. Cochrane Database Syst Rev. 2013. PMID: 23986525 Free PMC article. Review.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal